Pharma Update

Hemlibra: Expecting continued market share gains globally The global standard of care with ~40% patient share reached in US/EU5* Steady patient share gains in US and globally 50% 40% 30% 20% 10% 0% US/EU5 total Hemophilia A patient share Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 20 20 20 20 21 21 21 21 22 22 22 22 23 23 -Hemlibra Hemlibra performance update • · ~21,000 patients treated globally Roche HEMLIBRA. emicizumab-kxwh Outstanding profile with >2/3 of patients on monthly or Q2W SC dosing and zero risk of developing inhibitors over time. • Non-inhibitor approved in >100 countries and reimbursed in 58 • Further penetration among moderate/severe patients who remain uncontrolled on FVIII ongoing; high satisfaction amongst switchers Outlook • Focus on access opportunities in non-inhibitors (severe and moderate); some countries already with ~70% non-inhibitor patient share (CA, UK, FR) • Driving growth in key accounts which are below peak share potential • Increasing international access Further growth potential in our Hemophilia A franchise: SPK-8011 gene therapy program and NXT-007 bispecific development ongoing US/EU5 Patient Share within Hemlibra labelled population, source: affiliate data (UK NHS Providers, US sales volume triangulated with IQVIA claims data, DE, ES, IT field force, France volumes); Q2W= every two weeks dosing * 60 60

View entire presentation